AstraZeneca: lupus drug candidate shows promise in Phase III trial November 16, 2021 Auto Bot Clinical Development 0 According to the pharma firm, Saphnelo (anifromulab) combined with standard therapy resulted in reduction of systemic lupus erythematosus disease activity.